Quebec Adds Momentum To Canadian Biosimilar Switching
Canadian Province Becomes Latest To Introduce Switching Program
Quebec has become the latest Canadian province to introduce a biosimilar switching program, following in the footsteps of British Columbia, Alberta and New Brunswick.
You may also be interested in...
Biosimilars Canada president Jim Keon has urged the province of Ontario to follow other Canadian provinces by adopting a biosimilar switching policy for its public drug program, in order to cut costs on biologics and re-invest in the healthcare system.
Having recently announced plans to launch a further four biosimilar products in the next four years, Fresenius Kabi has disclosed the latest on its bid to introduce pegfilgrastim, which has been hamstrung in the US by delayed inspections.
New Brunswick has become the latest Canadian province to introduce a biosimilar switching program, with the newly-introduced scheme covering several biologic molecules.